-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Furosemide in Congestive Heart Failure (Heart Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Furosemide in Congestive Heart Failure (Heart Failure) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Furosemide in Congestive Heart Failure (Heart Failure) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rigosertib Sodium in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rigosertib Sodium in Metastatic Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rigosertib Sodium in Metastatic Melanoma Drug Details: Rigosertib (Estybon, ON...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rigosertib Sodium in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rigosertib Sodium in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rigosertib Sodium in Non-Small Cell Lung Cancer Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rigosertib Sodium in Lung Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rigosertib Sodium in Lung Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rigosertib Sodium in Lung Adenocarcinoma Drug Details: Rigosertib (Estybon, ON...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rigosertib Sodium in Squamous Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rigosertib Sodium in Squamous Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rigosertib Sodium in Squamous Non-Small Cell Lung...
-
Product Insights
NewNavidea Biopharmaceuticals Inc Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Navidea Biopharmaceuticals Inc Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Navidea Biopharmaceuticals Inc (Navidea) is a biopharmaceutical company that develops precision immunodiagnostic agents and immunotherapeutics. Its pipeline products include Tc99m tilmanocept for Kaposi's, NAS, Cardiovascular diseases, Sentinal Node Biopsy, and Solid tumors lymphatic mapping; and NAV4694 for Alzheimer's Disease. Navidea by utilizing its Manocept platform develops multiple precision-targeted products to improve patient care by identifying pathways and sites of...
-
Product Insights
NewQuarterly Sugar Confectionery pricing trends in the United States
Empower your strategies with our Quarterly Sugar Confectionery pricing trends in the United States report and make more profitable business decisions. Consumers’ preferences for stores are most heavily influenced by pricing and promotions, but brands and retailers continue to adjust prices and promotions based on insufficient information from expensive, drawn-out, and incomplete audits of rival techniques. Brands and retailers can benefit from the unique intelligence provided by GlobalData Ecommerce Price Tracker, covering millions of SKUs, to identify, anticipate, and implement...
-
Sector Analysis
NewNorth America Hydrogen Market Trends and Analysis by Application Areas, Upcoming Projects, Policies and Key Players to 2030
North America Hydrogen Market Report Overview The active hydrogen capacity in North America stood at 1.4 mtpa as of April 2024 and the region holds a strong position in the global hydrogen market. Canada will continue to lead the region’s hydrogen market. This is attributed to GHI’s Spirit of Scotia project which is providing the country with a notable edge in terms of its production outlook. Key Use Sectors ·      Transportation ·      Iron & Steel ·      Power ·      Ammonia ·      ...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NA-831 in Rett Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NA-831 in Rett Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NA-831 in Rett Syndrome Drug Details: NA-831 (traneurocin) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Torsemide ER in Resistant Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Torsemide ER in Resistant Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Torsemide ER in Resistant Hypertension Drug Details: Torsemide (Soaanz) is a...